Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease
- 28 February 2006
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 151 (2), 521.e1-521.e4
- https://doi.org/10.1016/j.ahj.2005.10.021
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndromeJournal of the American College of Cardiology, 2004
- Atorvastatin Does Not Affect the Antiplatelet Potency of Clopidogrel When It Is Administered Concomitantly for 5 Weeks in Patients With Acute Coronary SyndromesCirculation, 2004
- Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular DiseaseCirculation, 2003
- Soluble CD40 Ligand in Acute Coronary SyndromesThe New England Journal of Medicine, 2003
- Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary InterventionJama-Journal Of The American Medical Association, 2002
- Association Between Enhanced Soluble CD40L and Prothrombotic State in HypercholesterolemiaCirculation, 2002
- CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanismNature Medicine, 2002
- Soluble CD40L and Cardiovascular Risk in WomenCirculation, 2001
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenThe New England Journal of Medicine, 1997
- The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable AnginaThe New England Journal of Medicine, 1994